Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study.
Adolescent
Adrenal Cortex Hormones
/ therapeutic use
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Efficiency
Female
Histamine H1 Antagonists
/ therapeutic use
Humans
Infant
Infant, Newborn
Male
Middle Aged
Mobile Applications
Rhinitis, Allergic
/ drug therapy
Symptom Assessment
Visual Analog Scale
Young Adult
Allergic rhinitis
MASK
antihistamines
asthma
conjunctivitis
corticosteroids
mobile health
treatment
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
12
11
2018
revised:
05
01
2019
accepted:
23
01
2019
pubmed:
6
4
2019
medline:
19
5
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
Sections du résumé
BACKGROUND
Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control.
OBJECTIVES
A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR.
METHODS
A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H
RESULTS
Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H
CONCLUSIONS
This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
Identifiants
pubmed: 30951790
pii: S0091-6749(19)30426-9
doi: 10.1016/j.jaci.2019.01.053
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Histamine H1 Antagonists
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-143.e6Informations de copyright
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. All rights reserved.